Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug parsaclisib gets extended trial for B-Cell patients

NCT ID NCT04509700

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offers continued access to the drug parsaclisib for people with B-cell cancers who were already benefiting from it in earlier trials. About 112 participants will keep taking the same dose, either alone or with other drugs, to monitor long-term safety and tolerability. The goal is to see if ongoing treatment remains safe and helpful.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Parsaclisib (alone or with itacitinib, ruxolitinib, or ibrutinib)
What this could lead to
If successful, this study could show that long-term parsaclisib is safe and helps keep B-cell cancers under control.
What could go wrong
This is an early-phase rollover study with no control group, so results may not prove effectiveness. Side effects from continued treatment are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

112 people

The number who actually took part.

Started

Aug 2020

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Currently enrolled and receiving treatment in an Incyte-sponsored clinical study of parsaclisib. * Currently tolerating treatment in the parent Protocol. * Currently receiving clinical benefit from treatment with parsaclisib as monotherapy or in combination therapy with Itacitinib, ruxolitinib, or ibrutinib as determined by the investigator. * Has at least stable disease, as determined by the investigator. * Has demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements. * Willingness and ability to comply with scheduled visits, treatment plans, including PJP prophylaxis, and any other study procedures indicated in this Protocol. * Willingness to avoid pregnancy or fathering children * Ability to comprehend and willingness to sign an ICF Exclusion Criteria: * Has been permanently discontinued from study treatment in the parent Protocol for any reason. * Able to access parsaclisib as monotherapy or in combination with itacitinib, ruxolitinib, or ibrutinib therapy outside a clinical study. * Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol. * Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B cell malignancies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell neoplasm Myeloproliferative Disorders non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B cell malignancies

Contacts and locations

Locations

  • Aarhus University Hospital

    Århus N, 08200, Denmark

  • Ap-Hp Groupe Hospitalier Saint-Louis Lariboisiere Fernand-Widal Site Saint Louis (Paris)

    Paris, 75010, France

  • Az Groeninge

    Kortrijk, 08500, Belgium

  • Azienda Ospedaliera Ospedali Riuniti Villa Sofia - Cervello

    Palermo, 90146, Italy

  • Azienda Ospedaliero Universitaria Maggiore Della Carita Di Novara

    Novara, 28100, Italy

  • Azienda Ospedaliero Universitaria Pisana - Ospedale S. Chiara

    Pisa, 56126, Italy

  • Azienda Ospedaliero-Universitaria Careggi (Aouc)

    Florence, 50134, Italy

  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

    Milan, 20162, Italy

  • Baylor Scott White Univeristy Medical Center

    Dallas, Texas, 75246, United States

  • Birmingham Heartlands Hospital

    Birmingham, B9 5SS, United Kingdom

  • California Cancer Associates For Research and Excellence

    Fresno, California, 93720, United States

  • Centre Antoine Laccassagne

    Nice, 06189, France

  • Centre Hospitalier Universitaire de Toulouse

    Toulouse, 31059, France

  • Chru Hopitaux de Tours Hospital Bretonneau

    Tours, 37000, France

  • Chru de Brest Hospital Morvan

    Brest, 29200, France

  • City of Hope National Medical Center

    Duarte, California, 31010, United States

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Cliniques Universitaires Ucl Saint-Luc

    Brussels, 01200, Belgium

  • Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano

    Milan, 20133, Italy

  • Comitato Etico Fondazione Irccs Istituto Nazionale Dei Tumori Milano

    Milan, 22162, Italy

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada, 89169, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Ege University Hospital

    Izmir, 35040, Turkey (Türkiye)

  • Fakultni Nemocnice V Motole

    Prague, 15000, Czechia

  • Fondazione Irccs Ca Granda Ospedale Maggiore

    Milan, 20122, Italy

  • Germans Trias I Pujol

    Badalona, 08916, Spain

  • Hadassah Hebrew University Medical Center Ein Karem Hadassah

    Jerusalem, 91120, Israel

  • Hattiesburg Clinic Hematology

    Hattiesburg, Mississippi, 39401, United States

  • Haukeland University Hospital

    Bergen, 05021, Norway

  • Hca Midwest Health-Research Medical Center

    Kansas City, Missouri, 66211, United States

  • Hokuyukai Sapporo Hokuyu Hospital

    Sapporo, 003-0006, Japan

  • Hospital Clinic Barcelona

    Barcelona, 08036, Spain

  • Hospital Clinic I Provincial

    Barcelona, 08036, Spain

  • Hospital Clinico Universitario de Salamanca

    Salamanca, 37007, Spain

  • Hospital Del Mar

    Barcelona, 08003, Spain

  • Hospital General Universitario Gregorio Maranon

    Madrid, 28009, Spain

  • Hospital General Unviersitario de Alicante

    Alicante, 03010, Spain

  • Hospital Universitaire Pitie-Salpetriere

    Paris, 75013, France

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Fundacin Jimnez Daz

    Madrid, 28040, Spain

  • Hospital Universitario Hm Sanchinarro

    Madrid, 28050, Spain

  • Hospital Universitario Quironsalud Madrid

    Pozuelo de Alarcón, 28233, Spain

  • Hospital Universitario Virgen Del Rocio

    Seville, 41013, Spain

  • Innovative Clinical Research Institute

    Long Beach, California, 90805, United States

  • Institut Catala Doncologia - Hospital Duran I Reynals

    L'Hospitalet de Llobregat, 08908, Spain

  • Irb of Kobe City Medical Center General Hospital

    Kobe, 650-0047, Japan

  • Istanbul Medipol Universitesi Ibagcilar Medipol Mega Universitesi Hastanesi

    Istanbul, 34214, Turkey (Türkiye)

  • Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori

    Meldola (FC), 47014, Italy

  • Jrc Aichi Medical Center Nagoya Daini Hospital

    Nagoya, 466-8650, Japan

  • Juntendo University Hospital

    Bunkyō City, 113-8431, Japan

  • Kansai Medical University Hospital

    Hirakata, 573-1191, Japan

  • Karolinska University Hospital Solna

    Stockholm, 171 76, Sweden

  • Knight Cancer Institute At Oregon Health and Science University

    Portland, Oregon, 97239, United States

  • Lstituto Di Ematologia Lorenzo Ea.Seragnoli Universita Degli Studi Di Bologna - Policlinico S. Or

    Bologna, 40138, Italy

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Mayo Clinic Rochester

    Phoenix, Arizona, 85054, United States

  • Medical University of Vienna

    Vienna, 01090, Austria

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Miyagi Cancer Center

    Miyagi, 981-1293, Japan

  • National Cancer Center Hospital

    Chūō, 104-0045, Japan

  • National Hospital Org. Hokkaido Cancer Center

    Sapporo, 003-0804, Japan

  • Nho Matsumoto Medical Center

    Matsumoto-shi, 399-8701, Japan

  • Niigata Cancer Center Hospital

    Niigata, 951-8566, Japan

  • Nippon Medical School Hospital

    Tokyo, 113-8603, Japan

  • Osaka Metropolitan University Hospital

    Osaka, 545-8585, Japan

  • Ospedale Sant. Eugenio

    Roma, 00144, Italy

  • Ospedale Santa Maria Delle Croci

    Ravenna, 48121, Italy

  • Petz Aladar County Teaching Hospital

    Győr, 09024, Hungary

  • Rabin Medical Center - Beilinson Hospital

    Petah Tikva, 49100, Israel

  • Rcca Md, Llc

    Bethesda, Maryland, 20817, United States

  • Rigshospitalet

    Copenhagen, 02100, Denmark

  • Rocky Mountain Cancer Center

    Aurora, Colorado, 80012, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • Rush University Medical Center-Consultants in Hematology

    Chicago, Illinois, 60612, United States

  • Saint Luke'S Hospital of Kansas City

    Kansas City, Missouri, 64111, United States

  • Samodzielny Publiczny Szpital Kliniczny Nr 1

    Wroclaw, 20-081, Poland

  • Sheba Medical Center

    Tel Litwinsky, 5265601, Israel

  • Sjaellands Universitetshospital

    Roskilde, 04000, Denmark

  • Sp Zoz Szpital Uniwersytecki

    Kracow, 31-501, Poland

  • Start Madrid - Ciocc

    Boadilla del Monte, 28660, Spain

  • Szpital Specjalistyczny Im. Jedrzeja Sniadeckiego W Nowym Saczu

    Nowy Sącz, 33-300, Poland

  • Tenri Hospital

    Tenri, 632-8552, Japan

  • The Catholic University of Korea Seoul St. Mary'S Hospital

    Seoul, 06591, South Korea

  • The Ohio State University

    Columbus, Ohio, 43210, United States

  • Tohoku University Hospital

    Sendai, 980-8574, Japan

  • Tokai University Hospital

    Isehara, 259-1193, Japan

  • Tokyo Medical University Hospital

    Shinjuku, 160-0023, Japan

  • Uab Comprehensive Cancer Center

    Birmingham, Alabama, 35233, United States

  • Universita Di Napoli Federico Ii

    Naples, 80131, Italy

  • Universitair Ziekenhuis Gent (Uz Gent)

    Ghent, 09000, Belgium

  • Universitaire Ziekenhuis Leuven - Gasthuisberg

    Leuven, 03000, Belgium

  • University Hospital Hradec Kralove

    Hradec Králové, 50005, Czechia

  • University Hospital Kralovkse Vinohrady

    Prague, Czechia

  • University Hospital Kyoto Prefectural University of Medicine

    Kyoto, 602-8566, Japan

  • University Hospitals Case Medical Center

    Cleveland, Ohio, 44106, United States

  • University of Alabama At Birmingham

    Birmingham, Alabama, 35233, United States

  • University of Arizona Cancer Center-Out Pt.

    Tucson, Arizona, 85719, United States

  • University of Bologna Institute of Haematology L E A Seragnoli

    Bologna, 40126, Italy

  • University of Fukui Hospital

    Yoshida-gun, 910-1193, Japan

  • University of Kansas Hospital Authority

    Westwood, Kansas, 66205, United States

  • University of Michigan Cancer Center

    Ann Arbor, Michigan, 48109, United States

  • University of Washington-Seattle Cancer Care Alliance

    Seattle, Washington, 98109-4405, United States

  • Univerzita Karlova V Praze 1. Lekarska Fakulta

    Prague, 128 00, Czechia

  • Wwcoit Im. M. Kopernika W Lodzi

    Lodz, 93-513, Poland

  • Yokohama Municipal Citizens Hospital

    Yokohama, 221-0855, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.